ARTICLE | Clinical News
Alvocidib: Interim Phase II data
September 1, 2014 7:00 AM UTC
Interim data from an open-label, U.S. Phase II trial in 165 patients with previously untreated AML showed that 1 cycle of alvocidib plus cytarabine and mitoxantrone led to a complete response rate, th...